Asset profile
Trastuzumab rezetecan
Antibody–drug conjugate
Phase 3underway
Evidence outlook · registrational
HR+/HER2- Metastatic Breast Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-12-31.
Also in development:Non-Small Cell Lung Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
129 competitors in this universe: 13 direct rivals (same mechanism and indication), 0 same-class, 116 same-indication; 83 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Trastuzumab Rezetecan: this drug | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Trastuzumab Deruxtecan | Approved | Antibody–drug conjugate | HER2 | ||
| Zanidatamab | Approved | Multispecific antibody | HER2 | ||
| Zongertinib | Approved | Small molecule | HER2, HER2 Mutant-selective | ||
| BL-M07D1 | Phase 3 | Antibody–drug conjugate | HER2 | ||
| DB-1303 | Phase 3 | Monoclonal antibody | HER2 | ||
| Disitamab Vedotin | Phase 3 | Antibody–drug conjugate | HER2 | ||
| Tucatinib | Phase 3 | Small molecule | HER2 | ||
| HRS-4508 | Phase 2 | Small molecule | HER2 | ||
| 177Lu-DWJ155 | Phase 1 | Radiopharmaceutical | HER2 | ||
| BL-M17D1 | Phase 1 | Antibody–drug conjugate | HER2 | ||
| KJ015 | Phase 1 | Monoclonal antibody | HER2 | ||
| MT-304 | Phase 1 | Cell therapy | HER2 | ||
| NVL-330 | Phase 1 | Small molecule | HER2 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 |
…and 114 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(85 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (8)
October 2026 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-10-31 · NCT06222879 · CT.gov ↗
What to watch
November 2026 (1)
Phase 1/2HER2-expressing Advanced Solid TumorsRecruiting
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
December 2026 (6)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2026-12 · NCT06840002 · CT.gov ↗
What to watch
Phase 2Advanced Salivary Gland CarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT05924256 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT05076682 · CT.gov ↗
What to watch
Phase 2HER2 Expression / Amplification in Patients With Biliary Tract CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT06413745 · CT.gov ↗
What to watch
Phase 3HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneActive not recruiting
Est. primary completion 2026-12-31 · NCT05424835 · CT.gov ↗
What to watch
2027 (26)
March 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-03 · NCT07416253 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03 · NCT06433609 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-03 · NCT07305246 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-03 · NCT06547736 · CT.gov ↗
What to watch
April 2027 (2)
May 2027 (2)
June 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06975475 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06975462 · CT.gov ↗
What to watch
Phase 3HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT06123494 · CT.gov ↗
What to watch
July 2027 (2)
August 2027 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-08-30 · NCT07778745 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug ConjugatesRecruiting
Est. primary completion 2027-09-11 · NCT07309770 · CT.gov ↗
What to watch
October 2027 (1)
November 2027 (1)
Phase 2Biliary Tract Cancer (BTC), First-line TherapyNot yet recruiting
Est. primary completion 2027-11 · NCT07129018 · CT.gov ↗
What to watch
December 2027 (8)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07281209 · CT.gov ↗
What to watch
Phase 2Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-12 · NCT07102901 · CT.gov ↗
What to watch
Phase 2HER2 Expression Gastric Cancer/Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-12 · NCT05671822 · CT.gov ↗
What to watch
Phase 3Early-stage or Locally Advanced HER2-positive Breast CancerActive not recruiting
Est. primary completion 2027-12 · NCT07196774 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07489703 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07307287 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch
2028 (29)
January 2028 (2)
February 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02-01 · NCT07383818 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruiting
Est. primary completion 2028-02-01 · NCT07466303 · CT.gov ↗
What to watch
March 2028 (3)
Phase 3PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast CancerRecruiting
Est. primary completion 2028-03 · NCT07111832 · CT.gov ↗
What to watch
Phase 2Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)Not yet recruiting
Est. primary completion 2028-03-30 · NCT07776171 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-03-31 · NCT06788197 · CT.gov ↗
What to watch
June 2028 (7)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07618923 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT07497386 · CT.gov ↗
What to watch
Phase 2HER2-positive Locally Advanced or Metastatic Biliary Tract CancerRecruiting
Est. primary completion 2028-06 · NCT06778031 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2028-06-01 · NCT07624201 · CT.gov ↗
What to watch
Phase 2Chemotherapy-Induced Nausea and Vomiting (CINV)Recruiting
Est. primary completion 2028-06-01 · NCT07726433 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder CancerNot yet recruiting
Est. primary completion 2028-06-05 · NCT07639983 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT07037199 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal CancerNot yet recruiting
Est. primary completion 2028-07 · NCT06666166 · CT.gov ↗
What to watch
Phase 2Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma RecurrentRecruiting
Est. primary completion 2028-07-01 · NCT07241793 · CT.gov ↗
What to watch
August 2028 (2)
September 2028 (4)
Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07177950 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-09-30 · NCT07817082 · CT.gov ↗
What to watch
Phase 3Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2028-09-30 · NCT07669610 · CT.gov ↗
What to watch
Phase 3Breast Cancer, Triple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2028-09-30 · NCT07760844 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-10-15 · NCT07317778 · CT.gov ↗
What to watch
December 2028 (6)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT05769010 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07631884 · CT.gov ↗
What to watch
Phase 2HER2-positive Early Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07560475 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07382687 · CT.gov ↗
What to watch
Phase 4Breast Cancer, HER2-positive Breast Cancer, Early-stage Breast Cancer, Locally Advanced Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07589699 · CT.gov ↗
What to watch
2029 (10)
January 2029 (1)
Phase 2Breast Cancer, HER2-positive Breast CancerNot yet recruiting
Est. primary completion 2029-01-31 · NCT07417241 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-03 · NCT07699952 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2HER2-positive Breast CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07787338 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05-01 · NCT06927180 · CT.gov ↗
What to watch
June 2029 (2)
August 2029 (2)
Phase 2Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 PositiveNot yet recruiting
Est. primary completion 2029-08-01 · NCT06881017 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-08-30 · NCT07781202 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Advanced Colorectal CancerRecruiting
Est. primary completion 2029-09 · NCT07676162 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07836543 · CT.gov ↗
What to watch
2030 (8)
April 2030 (1)
Phase 3HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant TherapyActive not recruiting
Est. primary completion 2030-04 · NCT06126640 · CT.gov ↗
What to watch
June 2030 (3)
Phase 1/2Ovarian CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT06990516 · CT.gov ↗
What to watch
Phase 3Ovarian CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT06990503 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-06-15 · NCT07203729 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2HER2-positive Advanced Breast Cancer, Brain Metastases, RadiotherapyRecruiting
Est. primary completion 2030-07-30 · NCT07100600 · CT.gov ↗
What to watch
October 2030 (1)
Phase 3Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-10 · NCT07118527 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-06 · NCT07630103 · CT.gov ↗
What to watch
2032 (1)
August 2032 (1)
Phase 2HER2-positive Breast Cancer, Early Breast Cancer (EBC)Not yet recruiting
Est. primary completion 2032-08 · NCT07856303 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.